Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sa...
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-14
- Target Recruit Count
- 50
- Registration Number
- NCT06059118
- Locations
- 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 15
- Registration Number
- NCT05717153
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Emily K. Sims
- Target Recruit Count
- 70
- Registration Number
- NCT05594563
- Locations
- 🇺🇸
IU Health Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Children's Mercy Hospital, Kansas City, Kansas, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Aminex Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05500508
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix/Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic - Minnesota, Rochester, Minnesota, United States
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 131
- Registration Number
- NCT04301843
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸UCSF Benioff Children's Hospital Oakland-, Oakland, California, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Oral AMXT 1501 Dicaprate in Combination With DFMO
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Aminex Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03536728
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Oncology - San Antonio, San Antonio, Texas, United States
🇺🇸Virginia Cancer Center, Fairfax, Virginia, United States
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT02796261
- Locations
- 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Chemoprevention of Gastric Carcinogenesis
- Conditions
- Interventions
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 91
- Registration Number
- NCT02794428
- Locations
- ðŸ‡ðŸ‡³
Ministry of Health, Hospital de Occidente, Copán, Honduras
🇵🇷University of Puerto Rico, Comprehensive Cancer Center, San Juan, Puerto Rico
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 500
- Registration Number
- NCT02559778
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸St. Lukes, Boise, Idaho, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 140
- Registration Number
- NCT02395666
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Children's Hospital and Clinics on Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.